Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Chlorphenamine
- Accession Number
- DB01114 (APRD00001, DB09440)
- Type
- Small Molecule
- Groups
- Approved
- Description
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]
- Structure
Structure for DB01114 (Chlorphenamine)
- Synonyms
- 1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
- 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine
- 2-[p-chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine
- 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
- Chlorophenylpyridamine
- Chlorphenamin
- Chlorphenaminum
- Chlorpheniramine
- Chlorpheniramine polistirex
- Chlorpheniraminum
- Clorfenamina
- Clorfeniramina
- γ-(4-chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine
- γ-(4-chlorophenyl)-γ-(2-pyridyl)propyldimethylamine
- Product Ingredients
Ingredient UNII CAS InChI Key Chlorpheniramine gluconate 79YPK3BAIT 25387-68-2 OCMSTKFGYJZBIY-IFWQJVLJSA-N Chlorpheniramine hydrochloride 5S6VUP419V 56343-98-7 NOXNCSQBTYNMHD-UHFFFAOYSA-N Chlorpheniramine maleate V1Q0O9OJ9Z 113-92-8 DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine tannate 72JT935YTT 1405-56-7 KOOFUFFGNZKXFG-HBNMXAOGSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Chlorpheniramine Maleate Injection USP Liquid 10 mg Intramuscular; Intravenous; Subcutaneous Omega Laboratories Ltd Not applicable Not applicable Canada 
Chlortripolon Inj 10mg/ml Liquid 10 mg Intramuscular; Intravenous; Subcutaneous Schering Plough 1953-12-31 1999-08-04 Canada - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End 4 Hour Allergy Relief Tablet 4 mg/1 Oral Better Living Brands 1992-12-19 Not applicable US 
Aller-chlor Tablet 4 mg/1 Oral Lake Erie Medical Dba Quality Care Produts Llc 1992-12-19 2018-05-11 US Aller-chlor Tablet 4 mg/1 Oral Rugby 1992-12-19 Not applicable US Aller-chlor Tablet 4 mg/1 Oral A S Medication Solutions 1992-12-19 2017-06-20 US Aller-Chlor Syrup 2 mg/5mL Oral Rugby 2003-01-17 Not applicable US Aller-chlor Syrup 2 mg/5mL Oral Rugby 2014-03-20 Not applicable US Allergy Tablet 4 mg/1 Oral A S Medication Solutions 1992-12-19 2017-06-20 US Allergy Tablet 4 mg/1 Oral Supervalu 1992-12-19 Not applicable US Allergy Tablet 4 mg/1 Oral Kroger 1987-07-15 2017-12-01 US Allergy Tablet 4 mg/1 Oral Remedy Repack 2009-02-26 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End 999 Cold Remedy Chlorpheniramine maleate (2 mg/6000mg) + Acetaminophen (100 mg/6000mg) Capsule Oral China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. 2003-07-03 Not applicable US 999 Cold Remedy Granular Chlorpheniramine maleate (4 mg/90g) + Acetaminophen (200 mg/90g) Granule Oral China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. 2003-07-03 Not applicable US 999 Ganmaoling Cold Chlorpheniramine maleate (2 mg/1) + Acetaminophen (100 mg/1) + Caffeine (2 mg/1) Capsule Oral Kingsway 2012-07-30 Not applicable US Acetaminophen, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride Chlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1) Tablet, coated Oral AAA Pharmaceutical, Inc. 2012-12-28 Not applicable US Acetaminophen, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride Chlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1) Tablet, coated Oral AAA Pharmaceutical, Inc. 2012-12-28 Not applicable US Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hydrochloride Chlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1) Tablet, coated Oral AAA Pharmaceutical, Inc. 2012-12-28 Not applicable US Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hydrochloride Chlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1) Tablet, coated Oral AAA Pharmaceutical, Inc. 2012-12-28 Not applicable US Acti PE Chlorpheniramine maleate (4 mg/1) + Phenylephrine hydrochloride (10 mg/1) Tablet Oral P & L Development, LLC 2015-02-28 Not applicable US Actifed PE Chlorpheniramine maleate (4 mg) + Phenylephrine hydrochloride (10 mg) Tablet Oral Mcneil Consumer Healthcare Division Of Johnson & Johnson Inc Not applicable Not applicable Canada Actifed PE Plus Chlorpheniramine maleate (2 mg) + Acetaminophen (500 mg) + Phenylephrine hydrochloride (5 mg) Tablet Oral Mcneil Consumer Healthcare Division Of Johnson & Johnson Inc Not applicable Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Atuss DS Tannate Suspension Chlorpheniramine maleate (4 mg/5mL) + Dextromethorphan hydrobromide (30 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL) Suspension Oral Atley Pharmaceuticals 2006-11-21 2017-08-29 US Chlorpheniramine Maleate Chlorpheniramine maleate (4 mg/1) Tablet Oral Cardinal Health 2011-06-06 2018-01-25 US DryMax Chlorpheniramine maleate (4 mg/5mL) + Methscopolamine nitrate (1.25 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL) Syrup Oral Jay Mac Pharmaceuticals 2010-01-18 2016-10-13 US Lexuss 210 Chlorpheniramine maleate (2 mg/5mL) + Codeine phosphate (10 mg/5mL) Liquid Oral Centurion Labs 2009-04-15 2017-08-17 US Poly Hist Pd Chlorpheniramine maleate (2 mg/5mL) + Pyrilamine maleate (12.5 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL) Liquid Oral Poly Pharmaceuticals 2004-08-05 2017-08-29 US R-Tanna Chlorpheniramine tannate (9 mg/1) + Phenylephrine tannate (25 mg/1) Tablet Oral Pd Rx Pharmaceuticals, Inc. 2005-10-19 2016-12-21 US R-Tanna Chlorpheniramine tannate (9 mg/1) + Phenylephrine tannate (25 mg/1) Tablet Oral Prasco, Laboratories 2005-10-19 2016-10-13 US R-Tanna Pediatric Suspension Chlorpheniramine tannate (4.5 mg/5mL) + Phenylephrine tannate (5 mg/5mL) Suspension Oral Prasco, Laboratories 2010-02-03 2016-10-13 US Sildec PE DM Chlorpheniramine maleate (4 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL) + Phenylephrine hydrochloride (12.5 mg/5mL) Syrup Oral Rebel Distributors 2010-03-31 2017-11-04 US - International/Other Brands
- Chlo-Amine / Chlor-Trimeton (Schering-Plough) / Clofeniramina / Haynon / Piriton (GlaxoSmithKline)
- Categories
- Anti-Allergic Agents
- Antihistamines for Systemic Use
- Antipruritics
- Central Nervous System Depressants
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 CYP3A7 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Dermatologic Agents
- Histamine Agents
- Histamine Antagonists
- Histamine H1 Antagonists
- Neurotransmitter Agents
- Pheniramine
- Propylamine Derivatives
- Pyridines
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Substituted Alkylamines
- UNII
- 3U6IO1965U
- CAS number
- 132-22-9
- Weight
- Average: 274.788
Monoisotopic: 274.123676325 - Chemical Formula
- C16H19ClN2
- InChI Key
- SOYKEARSMXGVTM-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
- IUPAC Name
- [3-(4-chlorophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
- SMILES
- CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
Pharmacology
- Indication
For the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.
- Structured Indications
- Pharmacodynamics
In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Chlorpheniramine, is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
- Mechanism of action
Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Target Actions Organism AHistamine H1 receptor antagonistHuman USodium-dependent serotonin transporter inhibitorHuman USodium-dependent noradrenaline transporter inhibitorHuman USodium-dependent dopamine transporter inhibitorHuman - Absorption
Well absorbed in the gastrointestinal tract.
- Volume of distribution
- Not Available
- Protein binding
72%
- Metabolism
Primarily hepatic via Cytochrome P450 (CYP450) enzymes.
- Route of elimination
- Not Available
- Half life
21-27 hours
- Clearance
- Not Available
- Toxicity
Oral LD50 (rat): 306 mg/kg; Oral LD50 (mice): 130 mg/kg; Oral LD50 (guinea pig): 198 mg/kg [Registry of Toxic Effects of Chemical Substances. Ed. D. Sweet, US Dept. of Health & Human Services: Cincinatti, 2010.] Also a mild reproductive toxin to women of childbearing age.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Chlorphenamine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Chlorphenamine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Chlorphenamine. Experimental 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may decrease the sedative activities of Chlorphenamine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorphenamine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Chlorphenamine is combined with 7-Nitroindazole. Experimental Abiraterone The serum concentration of Chlorphenamine can be increased when it is combined with Abiraterone. Approved Acepromazine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Aceprometazine. Approved Acetyl sulfisoxazole The metabolism of Chlorphenamine can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Adipiplon The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorphenamine. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorphenamine. Approved, Illicit, Investigational Amiodarone The metabolism of Chlorphenamine can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorphenamine. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorphenamine. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Chlorphenamine. Approved Amperozide The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amperozide. Experimental Amphetamine Amphetamine may decrease the sedative activities of Chlorphenamine. Approved, Illicit, Investigational Apalutamide The serum concentration of Chlorphenamine can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Chlorphenamine can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorphenamine. Approved, Investigational Artemether The metabolism of Chlorphenamine can be decreased when combined with Artemether. Approved Articaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Chlorphenamine. Approved Atazanavir The metabolism of Chlorphenamine can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Chlorphenamine can be decreased when combined with Atomoxetine. Approved Azaperone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Azaperone. Investigational, Vet Approved Azelastine Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Chlorphenamine. Approved Barbital The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benzocaine. Approved, Investigational Benzphetamine Benzphetamine may decrease the sedative activities of Chlorphenamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benzyl alcohol. Approved Benzylpenicilloyl Polylysine Chlorphenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorphenamine. Approved, Investigational Betaxolol The metabolism of Chlorphenamine can be decreased when combined with Betaxolol. Approved, Investigational Boceprevir The metabolism of Chlorphenamine can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Chlorphenamine can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Chlorphenamine can be decreased when it is combined with Bosentan. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorphenamine. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Chlorphenamine. Approved Brotizolam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bupivacaine. Approved, Investigational Buprenorphine Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Chlorphenamine can be decreased when combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Chlorphenamine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorphenamine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Chlorphenamine. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorphenamine. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Canertinib. Investigational Carbamazepine The metabolism of Chlorphenamine can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Chlorphenamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlorphenamine. Approved Celecoxib The metabolism of Chlorphenamine can be decreased when combined with Celecoxib. Approved, Investigational Ceritinib The serum concentration of Chlorphenamine can be increased when it is combined with Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Chlorphenamine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorphenamine. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chloroprocaine. Approved Chloroquine The metabolism of Chlorphenamine can be decreased when combined with Chloroquine. Approved, Investigational, Vet Approved Chlorphentermine Chlorphentermine may decrease the sedative activities of Chlorphenamine. Illicit, Withdrawn Chlorpromazine The metabolism of Chlorphenamine can be decreased when combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chlorphenamine. Approved Cholecalciferol The metabolism of Chlorphenamine can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cimetidine The metabolism of Chlorphenamine can be decreased when combined with Cimetidine. Approved, Investigational Cinacalcet The metabolism of Chlorphenamine can be decreased when combined with Cinacalcet. Approved Cinchocaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cinchocaine. Approved, Vet Approved Citalopram The metabolism of Chlorphenamine can be decreased when combined with Citalopram. Approved Clarithromycin The metabolism of Chlorphenamine can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Chlorphenamine can be decreased when combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Chlorphenamine. Approved Clobazam The metabolism of Chlorphenamine can be decreased when combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Chlorphenamine is combined with clomethiazole. Investigational Clomipramine The metabolism of Chlorphenamine can be decreased when combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Chlorphenamine. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Chlorphenamine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorphenamine. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clothiapine. Experimental Clotrimazole The metabolism of Chlorphenamine can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Chlorphenamine can be decreased when combined with Clozapine. Approved Cobicistat The serum concentration of Chlorphenamine can be increased when it is combined with Cobicistat. Approved Cocaine The metabolism of Chlorphenamine can be decreased when combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Chlorphenamine. Approved, Illicit Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Chlorphenamine. Approved, Investigational Crizotinib The metabolism of Chlorphenamine can be decreased when combined with Crizotinib. Approved Cyclizine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorphenamine. Approved Cyclopropane The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclopropane. Experimental Cyclosporine The metabolism of Chlorphenamine can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Chlorphenamine. Approved Dabrafenib The serum concentration of Chlorphenamine can be decreased when it is combined with Dabrafenib. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dapoxetine is combined with Chlorphenamine. Investigational Darifenacin The metabolism of Chlorphenamine can be decreased when combined with Darifenacin. Approved, Investigational Darunavir The serum concentration of Chlorphenamine can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Chlorphenamine can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Chlorphenamine can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Chlorphenamine can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Chlorphenamine. Approved Desipramine The metabolism of Chlorphenamine can be decreased when combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenamine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorphenamine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dexmedetomidine. Approved, Vet Approved Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Chlorphenamine. Approved, Illicit Dextromoramide The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Chlorphenamine. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Diethyl ether. Experimental Diethylpropion Diethylpropion may decrease the sedative activities of Chlorphenamine. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorphenamine. Approved, Illicit Dihydroergotamine The metabolism of Chlorphenamine can be decreased when combined with Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Chlorphenamine can be decreased when combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chlorphenamine. Approved Diphenhydramine The metabolism of Chlorphenamine can be decreased when combined with Diphenhydramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorphenamine. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doramectin. Vet Approved Dosulepin The metabolism of Chlorphenamine can be decreased when combined with Dosulepin. Approved Doxepin The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxepin. Approved, Investigational Doxycycline The metabolism of Chlorphenamine can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Chlorphenamine is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved, Illicit Dronedarone The metabolism of Chlorphenamine can be decreased when combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Drotebanol. Experimental, Illicit Duloxetine The metabolism of Chlorphenamine can be decreased when combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Chlorphenamine. Approved, Investigational Eliglustat The metabolism of Chlorphenamine can be decreased when combined with Eliglustat. Approved Eltanolone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Chlorphenamine. Approved, Investigational Enzalutamide The serum concentration of Chlorphenamine can be decreased when it is combined with Enzalutamide. Approved Erythromycin The metabolism of Chlorphenamine can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Chlorphenamine. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorphenamine. Approved, Investigational Ethanol Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorphenamine. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Chlorphenamine. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Chlorphenamine. Approved Fencamfamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorphenamine. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorphenamine. Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Chlorphenamine. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluanisone. Experimental Fluconazole The metabolism of Chlorphenamine can be decreased when combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flunitrazepam. Approved, Illicit Fluoxetine The metabolism of Chlorphenamine can be decreased when combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorphenamine. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorphenamine. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorphenamine. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Chlorphenamine. Approved Fluvoxamine The metabolism of Chlorphenamine can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Chlorphenamine can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Chlorphenamine can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Chlorphenamine. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fospropofol. Approved, Illicit, Investigational Fusidic Acid The serum concentration of Chlorphenamine can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorphenamine. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gabapentin Enacarbil. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chlorphenamine. Approved, Illicit, Investigational Gepefrine Gepefrine may decrease the sedative activities of Chlorphenamine. Experimental Gepirone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorphenamine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The metabolism of Chlorphenamine can be decreased when combined with Haloperidol. Approved Halothane The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hexobarbital. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenamine. Approved, Investigational Hydrocodone Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorphenamine. Approved, Illicit Hydroxyamphetamine Hydroxyamphetamine may decrease the sedative activities of Chlorphenamine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved Idelalisib The metabolism of Chlorphenamine can be decreased when combined with Idelalisib. Approved Iloperidone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iloperidone. Approved Imatinib The metabolism of Chlorphenamine can be decreased when combined with Imatinib. Approved Imipramine The metabolism of Chlorphenamine can be decreased when combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indalpine. Investigational, Withdrawn Indinavir The metabolism of Chlorphenamine can be decreased when combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indiplon. Investigational Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Chlorphenamine. Approved Isavuconazole The serum concentration of Chlorphenamine can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Chlorphenamine can be decreased when combined with Isavuconazonium. Approved, Investigational Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Chlorphenamine. Approved, Vet Approved Isoniazid The metabolism of Chlorphenamine can be decreased when combined with Isoniazid. Approved, Investigational Isradipine The metabolism of Chlorphenamine can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Chlorphenamine can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Chlorphenamine can be increased when it is combined with Ivacaftor. Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Chlorphenamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Chlorphenamine can be decreased when combined with Ketoconazole. Approved, Investigational L-Tryptophan L-Tryptophan may increase the serotonergic activities of Chlorphenamine. Approved, Nutraceutical, Withdrawn Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorphenamine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorphenamine. Approved Lidocaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lidocaine. Approved, Vet Approved Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Chlorphenamine. Approved, Investigational Lithium The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lithium. Approved Lofentanil The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Chlorphenamine can be increased when used in combination with Lofexidine. Approved, Investigational Lopinavir The metabolism of Chlorphenamine can be decreased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Chlorphenamine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorphenamine. Approved Lorcaserin The metabolism of Chlorphenamine can be decreased when combined with Lorcaserin. Approved Lormetazepam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Chlorphenamine can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Chlorphenamine can be decreased when combined with Lovastatin. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Chlorphenamine. Approved Luliconazole The serum concentration of Chlorphenamine can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Chlorphenamine can be increased when combined with Lumacaftor. Approved Lumefantrine The metabolism of Chlorphenamine can be decreased when combined with Lumefantrine. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Chlorphenamine can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine The metabolism of Chlorphenamine can be decreased when combined with Manidipine. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorphenamine. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Chlorphenamine. Approved Medazepam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Melperone. Approved, Investigational Mephedrone Mephedrone may decrease the sedative activities of Chlorphenamine. Investigational Mephentermine Mephentermine may decrease the sedative activities of Chlorphenamine. Approved Mepivacaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorphenamine. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Chlorphenamine. Approved Methadone The metabolism of Chlorphenamine can be decreased when combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methadyl Acetate. Approved, Illicit Methamphetamine Methamphetamine may decrease the sedative activities of Chlorphenamine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlorphenamine. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Chlorphenamine. Approved Methotrimeprazine Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Chlorphenamine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methylphenobarbital. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Chlorphenamine. Approved, Investigational Metyrosine Chlorphenamine may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Chlorphenamine. Approved, Illicit Midomafetamine Midomafetamine may decrease the sedative activities of Chlorphenamine. Experimental, Illicit, Investigational Midostaurin The metabolism of Chlorphenamine can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Chlorphenamine can be increased when it is combined with Mifepristone. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved, Investigational Mirabegron The metabolism of Chlorphenamine can be decreased when combined with Mirabegron. Approved Mirtazapine Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mitotane The serum concentration of Chlorphenamine can be decreased when it is combined with Mitotane. Approved MMDA MMDA may decrease the sedative activities of Chlorphenamine. Experimental, Illicit Molindone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Chlorphenamine. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorphenamine. Approved Nefazodone The metabolism of Chlorphenamine can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Chlorphenamine can be decreased when combined with Nelfinavir. Approved Netupitant The serum concentration of Chlorphenamine can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Chlorphenamine can be increased when combined with Nevirapine. Approved Nicardipine The metabolism of Chlorphenamine can be decreased when combined with Nicardipine. Approved, Investigational Nilotinib The metabolism of Chlorphenamine can be decreased when combined with Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorphenamine. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Chlorphenamine. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorphenamine. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorphenamine. Approved, Investigational Olaparib The metabolism of Chlorphenamine can be decreased when combined with Olaparib. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Chlorphenamine. Approved Ondansetron The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Opium. Approved, Illicit Orphenadrine Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Osanetant. Investigational Osimertinib The serum concentration of Chlorphenamine can be increased when it is combined with Osimertinib. Approved Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorphenamine. Approved Oxetacaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxetacaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorphenamine. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorphenamine. Approved, Investigational, Vet Approved Palbociclib The serum concentration of Chlorphenamine can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorphenamine. Approved Panobinostat The serum concentration of Chlorphenamine can be increased when it is combined with Panobinostat. Approved, Investigational Paraldehyde Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The metabolism of Chlorphenamine can be decreased when combined with Paroxetine. Approved, Investigational Peginterferon alfa-2b The serum concentration of Chlorphenamine can be decreased when it is combined with Peginterferon alfa-2b. Approved Penfluridol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorphenamine. Approved, Vet Approved Pentobarbital The metabolism of Chlorphenamine can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved Perazine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorphenamine. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Chlorphenamine. Approved Phenazocine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenibut. Experimental Phenobarbital The metabolism of Chlorphenamine can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenoxyethanol. Approved Phentermine Phentermine may decrease the sedative activities of Chlorphenamine. Approved, Illicit Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Chlorphenamine. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Chlorphenamine. Approved Pipamperone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipotiazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Piritramide. Approved, Investigational Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Chlorphenamine. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pomalidomide. Approved Posaconazole The metabolism of Chlorphenamine can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole Chlorphenamine may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Chlorphenamine can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prilocaine. Approved Primidone The metabolism of Chlorphenamine can be increased when combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorphenamine. Approved, Vet Approved Promazine The metabolism of Chlorphenamine can be decreased when combined with Promazine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Chlorphenamine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Chlorphenamine. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorphenamine. Approved Proxibarbal The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Chlorphenamine is combined with PSD502. Investigational Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Chlorphenamine. Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Chlorphenamine. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorphenamine. Approved Quinidine The metabolism of Chlorphenamine can be decreased when combined with Quinidine. Approved, Investigational Quinine The metabolism of Chlorphenamine can be decreased when combined with Quinine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Chlorphenamine. Approved, Investigational Ranolazine The metabolism of Chlorphenamine can be decreased when combined with Ranolazine. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorphenamine. Approved Remoxipride The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Chlorphenamine. Approved, Investigational Rifabutin The metabolism of Chlorphenamine can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Chlorphenamine can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Chlorphenamine can be increased when combined with Rifapentine. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Chlorphenamine. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ritanserin. Investigational Ritobegron Ritobegron may decrease the sedative activities of Chlorphenamine. Investigational Ritonavir The metabolism of Chlorphenamine can be decreased when combined with Ritonavir. Approved, Investigational Rolapitant The metabolism of Chlorphenamine can be decreased when combined with Rolapitant. Approved, Investigational Romifidine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Romifidine. Vet Approved Ropinirole Chlorphenamine may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ropivacaine. Approved Rotigotine Chlorphenamine may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Chlorphenamine can be decreased when combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorphenamine. Approved Saquinavir The metabolism of Chlorphenamine can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Chlorphenamine can be decreased when used in combination with Sarilumab. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorphenamine. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The metabolism of Chlorphenamine can be decreased when combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorphenamine. Approved, Vet Approved Sildenafil The metabolism of Chlorphenamine can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Chlorphenamine can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Chlorphenamine can be increased when it is combined with Simeprevir. Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved St. John's Wort The serum concentration of Chlorphenamine can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Chlorphenamine can be increased when it is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine. Approved, Investigational Sulfisoxazole The metabolism of Chlorphenamine can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sultopride. Experimental Suvorexant Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tasimelteon. Approved, Investigational Telaprevir The metabolism of Chlorphenamine can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Chlorphenamine can be decreased when combined with Telithromycin. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Chlorphenamine. Approved, Investigational Terbinafine The metabolism of Chlorphenamine can be decreased when combined with Terbinafine. Approved, Investigational, Vet Approved Tetrabenazine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrodotoxin. Investigational Thalidomide Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiopental. Approved, Vet Approved Thioridazine Chlorphenamine may increase the arrhythmogenic activities of Thioridazine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorphenamine. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Chlorphenamine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tiapride. Approved, Investigational Ticlopidine The metabolism of Chlorphenamine can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tilidine. Experimental Tipranavir The metabolism of Chlorphenamine can be decreased when combined with Tipranavir. Approved, Investigational Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorphenamine. Approved, Investigational Tocilizumab The serum concentration of Chlorphenamine can be decreased when it is combined with Tocilizumab. Approved Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorphenamine. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Chlorphenamine. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Chlorphenamine. Approved, Investigational Tranylcypromine The metabolism of Chlorphenamine can be decreased when combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Chlorphenamine. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorphenamine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorphenamine. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Chlorphenamine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Valproic Acid. Approved, Investigational Vemurafenib The serum concentration of Chlorphenamine can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Chlorphenamine can be decreased when combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Veralipride. Experimental Verapamil The metabolism of Chlorphenamine can be decreased when combined with Verapamil. Approved Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Chlorphenamine. Approved Vinyl ether The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vinyl ether. Experimental Voriconazole The metabolism of Chlorphenamine can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorphenamine. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Chlorphenamine can be decreased when combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zolazepam. Vet Approved Zolpidem Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Chlorphenamine. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Chlorphenamine. Approved Zotepine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorphenamine. Approved, Investigational - Food Interactions
- Avoid alcohol.
- Take with food.
References
- Synthesis Reference
Anil M. Salpekar, John Johnson, "Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom." U.S. Patent US4631284, issued April, 1975.
US4631284- General References
- MSDS [Link]
- External Links
- Human Metabolome Database
- HMDB0001944
- KEGG Drug
- D07398
- KEGG Compound
- C06905
- PubChem Compound
- 2725
- PubChem Substance
- 46508253
- ChemSpider
- 2624
- BindingDB
- 35938
- ChEBI
- 52010
- ChEMBL
- CHEMBL505
- Therapeutic Targets Database
- DAP000336
- PharmGKB
- PA448960
- IUPHAR
- 1213
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Chlorpheniramine
- ATC Codes
- R06AB54 — Chlorphenamine, combinations
- R06AB — Substituted alkylamines
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
- AHFS Codes
- 04:04.20 — Propylamine Derivatives
- MSDS
- Download (72.8 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Healthy Volunteers 4 2 Completed Treatment Allergic Reactions 1 2 Recruiting Treatment Sunburn 1 2 Terminated Treatment Allergic Rhinitis (AR) 1 2 Unknown Status Treatment Rhinitis, Seasonal, Allergic 1 3 Unknown Status Treatment Acute Rhinitis / Flu-like Syndromes 1 3 Withdrawn Treatment Acute Rhinitis 1 4 Unknown Status Treatment Vitiligo 1 Not Available Completed Basic Science Hypovolaemia / Temperature Change, Body 1 Not Available Unknown Status Prevention Poisoning 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Amend
- Anip Acquisition Co.
- A-S Medication Solutions LLC
- Breckenridge Pharmaceuticals
- C.O. Truxton Inc.
- Cardinal Health
- Consolidated Midland Corp.
- Contract Pharm
- Cypress Pharmaceutical Inc.
- Deltex Pharmaceuticals Inc.
- Direct Dispensing Inc.
- Dispensing Solutions
- Edwards Pharmaceuticals
- Hi Tech Pharmacal Co. Inc.
- Iopharm Laboratories Inc.
- Ivax Pharmaceuticals
- Kowa Pharmaceuticals America Inc.
- Kraft Pharmaceutical Co. Inc.
- Larken Laboratories Inc.
- Liberty Pharmaceuticals
- Magna Pharmaceuticals
- Major Pharmaceuticals
- Mallinckrodt Inc.
- McNeil Laboratories
- Meda AB
- Misemer Pharmaceuticals Inc.
- Mismer Pharmace
- Nucare Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Pecos Pharmaceutical Inc.
- Perrigo Co.
- Physicians Total Care Inc.
- Prepackage Specialists
- Provident Pharmaceuticals LLC
- Qualitest
- Rico Pharmacal
- River's Edge Pharmaceuticals
- Rugby Laboratories
- S&P Healthcare
- Schering-Plough Inc.
- Time-Cap Labs
- Tya Pharmaceuticals
- Watson Pharmaceuticals
- Wockhardt Ltd.
- Dosage forms
Form Route Strength Capsule, liquid filled Oral Granule, effervescent Oral Tablet, effervescent Oral Syrup Oral 2 mg/5mL Tablet, coated Oral 4 mg/1 Liquid; tablet Intramuscular; Oral; Subcutaneous Liquid; tablet Oral; Parenteral Granule, for solution Oral Liquid Topical Tablet, chewable Oral Liquid Oral Suspension Oral Tablet, extended release Oral 12 mg/1 Tablet, extended release Oral 12 mg Kit; tablet; tablet, extended release Oral Tablet Oral 12 mg Tablet, film coated, extended release Oral 12 mg/1 Liquid Intramuscular; Intravenous; Subcutaneous 10 mg Syrup Oral 2.5 mg Kit; tablet Oral Kit Oral Kit Tablet, extended release Oral Tablet, sugar coated Oral Lozenge Oral 2 mg/1 Kit; powder, for solution Oral Kit Liquid Oral 2 mL/mL Liquid Oral 2 mg/5mL Kit; powder Oral Powder, for solution Oral Granule Oral Tablet Oral 4 mg/1 Capsule Oral 1.25 mg/1 Capsule Oral Solution Oral Suspension, extended release Oral Capsule, delayed release pellets Oral Tablet, multilayer Oral Tablet Oral 4 mg Capsule, extended release Oral Powder Oral Tablet, film coated Oral Tablet Oral Capsule, gelatin coated Oral Tablet, coated Oral Syrup Oral - Prices
Unit description Cost Unit Ahist 12 mg tablet 1.1USD tablet Myci chlor-tan 8 mg caplet 0.75USD caplet Chlorpheniramine powder 0.67USD g Chlor-trimeton allergy 0.31USD each Chlor-trimeton 8 mg repetab 0.24USD tablet Aller-chlor 4 mg tablet 0.06USD tablet Pediacare allergy solution 0.05USD ml Allergy 4 mg tablet 0.04USD tablet Chlorpheniramine 4 mg tablet 0.02USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US7863287 No 2007-02-28 2027-02-28 US US8062667 No 2009-03-29 2029-03-29 US US8790700 No 2007-03-15 2027-03-15 US US9066942 No 2012-01-03 2032-01-03 US US6383471 No 1999-04-06 2019-04-06 US US6248363 No 1999-11-23 2019-11-23 US US9107921 No 2012-01-03 2032-01-03 US
Properties
- State
- Liquid
- Experimental Properties
Property Value Source boiling point (°C) 142 °C Not Available water solubility 5500 mg/L (at 37 °C) BEILSTEIN logP 3.38 HANSCH,C ET AL. (1995) pKa 9.13 (at 25 °C) PERRIN,DD (1965) - Predicted Properties
Property Value Source Water Solubility 0.0519 mg/mL ALOGPS logP 3.74 ALOGPS logP 3.58 ChemAxon logS -3.7 ALOGPS pKa (Strongest Basic) 9.47 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 16.13 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 80.85 m3·mol-1 ChemAxon Polarizability 30.82 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9754 Blood Brain Barrier + 0.962 Caco-2 permeable + 0.8749 P-glycoprotein substrate Substrate 0.6136 P-glycoprotein inhibitor I Non-inhibitor 0.8782 P-glycoprotein inhibitor II Non-inhibitor 0.9376 Renal organic cation transporter Inhibitor 0.7916 CYP450 2C9 substrate Non-substrate 0.8026 CYP450 2D6 substrate Substrate 0.8919 CYP450 3A4 substrate Substrate 0.6472 CYP450 1A2 substrate Non-inhibitor 0.9046 CYP450 2C9 inhibitor Non-inhibitor 0.9096 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.9023 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7501 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.9183 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 3.3361 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8702 hERG inhibition (predictor II) Inhibitor 0.7145
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Pheniramines
- Direct Parent
- Pheniramines
- Alternative Parents
- Chlorobenzenes / Aralkylamines / Aryl chlorides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
- Substituents
- Pheniramine / Chlorobenzene / Halobenzene / Aralkylamine / Aryl chloride / Benzenoid / Monocyclic benzene moiety / Aryl halide / Heteroaromatic compound / Tertiary aliphatic amine
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- tertiary amino compound, pyridines, monochlorobenzenes (CHEBI:52010)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, Arai H, Iwata R, Fujii T, Komemushi S, Ido T, Itoh M, Sasaki H, Watanabe T, Yanai K: Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol. 2001 Nov;52(5):501-9. [PubMed:11736858]
- Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF 3rd, Guinosso PJ Jr, Lynch JJ Jr: Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995 Jan;76(1):110-9. [PubMed:8001268]
- Hasenohrl RU, Kuhlen A, Frisch C, Galosi R, Brandao ML, Huston JP: Comparison of intra-accumbens injection of histamine with histamine H1-receptor antagonist chlorpheniramine in effects on reinforcement and memory parameters. Behav Brain Res. 2001 Oct 15;124(2):203-11. [PubMed:11640974]
- Yasuda SU, Wellstein A, Likhari P, Barbey JT, Woosley RL: Chlorpheniramine plasma concentration and histamine H1-receptor occupancy. Clin Pharmacol Ther. 1995 Aug;58(2):210-20. [PubMed:7648771]
- Nicholson AN, Pascoe PA, Turner C, Ganellin CR, Greengrass PM, Casy AF, Mercer AD: Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol. 1991 Sep;104(1):270-6. [PubMed:1686208]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Serotonin:sodium symporter activity
- Specific Function
- Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
- Gene Name
- SLC6A4
- Uniprot ID
- P31645
- Uniprot Name
- Sodium-dependent serotonin transporter
- Molecular Weight
- 70324.165 Da
References
- Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Norepinephrine:sodium symporter activity
- Specific Function
- Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A2
- Uniprot ID
- P23975
- Uniprot Name
- Sodium-dependent noradrenaline transporter
- Molecular Weight
- 69331.42 Da
References
- Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Monoamine transmembrane transporter activity
- Specific Function
- Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A3
- Uniprot ID
- Q01959
- Uniprot Name
- Sodium-dependent dopamine transporter
- Molecular Weight
- 68494.255 Da
References
- Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J: In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 1998 Jun;26(6):536-9. [PubMed:9616188]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Quaternary ammonium group transmembrane transporter activity
- Specific Function
- Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
- Gene Name
- SLC22A2
- Uniprot ID
- O15244
- Uniprot Name
- Solute carrier family 22 member 2
- Molecular Weight
- 62579.99 Da
References
- Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Secondary active organic cation transmembrane transporter activity
- Specific Function
- Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
- Gene Name
- SLC22A1
- Uniprot ID
- O15245
- Uniprot Name
- Solute carrier family 22 member 1
- Molecular Weight
- 61153.345 Da
References
- Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
Drug created on June 13, 2005 07:24 / Updated on May 26, 2018 08:53